SCHEMBL4767787

SCHEMBL4767787

COC(=O)c1ccc(N(Cc2cccc(Cl)c2Cl)S(=O)(=O)c2ccccc2)cc1

nearest known ligand 0.59

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.59
RAB9A P51151 1/20 0.59
MAPT P10636 5/20 0.50
LMNA P02545 5/20 0.50
HTT P42858 3/20 0.50
ALDH1A1 P00352 2/20 0.50
KDM4E B2RXH2 1/20 0.50
SMN1; SMN2 Q16637 2/20 0.48
OXTR P30559 3/20 0.48
AVPR1A P37288 1/20 0.48
MEN1 O00255 3/20 0.46
KMT2A Q03164 3/20 0.46
PTGES O14684 1/20 0.44
MAPK1 P28482 1/20 0.44
PTPN1 P18031 1/20 0.44
GAA P10253 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4777409 0.86 ALDH1A1 (0.51) L3MBTL1RAB9AMAPTLMNAALDH1A1
SCHEMBL4777497 0.85 MAPT (0.49) L3MBTL1RAB9AMAPTLMNAHTT
SCHEMBL4768135 0.85 MAPT (0.49) L3MBTL1RAB9AMAPTLMNAHTT
SCHEMBL4773537 0.84 MAPT (0.51) L3MBTL1RAB9AMAPTLMNAHTT
SCHEMBL4776409 0.84 MAPT (0.48) L3MBTL1RAB9AMAPTLMNAHTT
SCHEMBL4773418 0.84 MAPT (0.45) L3MBTL1RAB9AMAPTLMNAHTT
SCHEMBL4767972 0.83 MAPT (0.48) L3MBTL1RAB9AMAPTLMNAHTT
SCHEMBL4793562 0.83 MAPT (0.53) L3MBTL1RAB9AMAPTLMNAHTT
SCHEMBL4774852 0.83 MAPT (0.47) L3MBTL1RAB9AMAPTLMNAHTT
SCHEMBL4768089 0.83 MAPT (0.47) L3MBTL1RAB9AMAPTLMNAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1942888-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS Cytokinetics, Inc. (US) 2008-07-16 EP claimed
US-20070135435-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INCORPORATED 2007-06-14 US claimed
WO-2007056078-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS CYTOKINETICS, INC. (US) 2007-05-18 WO claimed
EP-1942888-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS Cytokinetics, Inc. (US) 2008-07-16 EP disclosed
US-20070135435-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INCORPORATED 2007-06-14 US disclosed
WO-2007056078-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS CYTOKINETICS, INC. (US) 2007-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135435-A1 Certain chemical entities, compositions, and methods KIF5B, KIF2C, PLK1 L3MBTL1 2781/4885RAB9A 1213/4885MAPT 294/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.